ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Cardio Diagnostics Broadens Access to Precision Cardiovascular Care with New Practice Partnerships Across U.S. Mainland and Puerto Rico

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a pioneer in AI-powered precision cardiovascular medicine, today announced the continued expansion of its reach with a new cohort of healthcare practices across the United States now offering its innovative clinical blood tests, Epi+Gen CHD™ and PrecisionCHD™.

This group of adopters spans a wide range of care models - from concierge and direct primary care to functional and integrative medicine, demonstrating the growing appetite for proactive, personalized cardiovascular care.

These latest adopters are primarily independent practices deeply committed to modernizing the patient experience and championing heart disease prevention and early detection. Clinicians across diverse regions, from Arizona to Puerto Rico, are integrating Cardio Diagnostics’ advanced epigenetic-genetic tests into everyday practice to uncover heart attack risk and the presence of heart disease earlier and more precisely.

Cardio Diagnostics Adds 10 New Practices Across Five States and Puerto Rico

In the Midwest, forward-thinking practices in Indiana and Ohio are leading with personalized, root-cause approaches to medicine. These providers are rejecting one-size-fits-all care in favor of deep patient-provider relationships and holistic strategies. This makes them ideal partners for Cardio Diagnostics’ precision cardiovascular solutions, which identify risk based not only on genetic predisposition but also on lifestyle-influenced epigenetic changes.

Practices in Southern California and Arizona continue to push boundaries in patient-centric healthcare, offering high-touch, concierge services with an emphasis on prevention, long-term wellness, and longevity. By incorporating Cardio Diagnostics’ tests, these practices are expanding the clinical toolkit for managing chronic disease and supporting patients in optimizing their long-term heart health.

Cardio Diagnostics is also proud to welcome its first partner outside the continental U.S. A concierge practice, based in Puerto Rico, is now bringing AI-driven cardiovascular testing to its clientele from across the Caribbean, marking an exciting milestone in Cardio Diagnostics’ reach.

In addition to these independent practices, Cardio Diagnostics has also partnered with a nationally connected network of direct primary care providers, expanding access to its solutions through a broad infrastructure of like-minded, prevention-focused clinics. This collaboration supports the continued growth of the direct primary care movement and aligns with Cardio Diagnostics’ mission to embed precision heart health tools into care models that prioritize time, access, and individualized patient care.

Supporting the Shift Toward Preventive Cardiology

This diverse group of practices reflects the growing alignment between independent healthcare providers and emerging technologies designed to detect cardiovascular disease earlier, more accurately, and more affordably. From primary care innovators to integrative health experts, these practices are united by a shared vision: to move upstream and shift the paradigm from reaction to prevention.

As cardiovascular disease continues to be the leading cause of death globally, Cardio Diagnostics is committed to equipping clinicians with actionable, precision-driven tools that can meaningfully change outcomes. With this latest wave of partnerships, the company continues to deliver on that mission.

“The expansion of our solutions into such a broad spectrum of forward-thinking medical practices is a powerful validation of our mission,” said Meesha Dogan, Ph.D., CEO and co-founder of Cardio Diagnostics. “Whether you’re a patient in Indiana, California, Puerto Rico, or anywhere in between, access to earlier, more personalized insights about your heart health should be the standard, not the exception.”

About Cardio Diagnostics

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit https://cdio.ai/

Forward-Looking Statements

Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on results are discussed in the Current Report on Form 10-K for the period ended in December 31, 2024, and Form 10-Q for the period ended in March 31, 2025, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.